Kathrin Schanda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1365875/publications.pdf

Version: 2024-02-01

36 3,108 20 36 36 36 papers citations h-index g-index

36 36 36 2333
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation, 2016, 13, 280.	7.2	686
2	Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. Journal of Neuroinflammation, 2011, 8, 184.	7.2	379
3	Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology, 2017, 89, 900-908.	1.1	278
4	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	1.9	228
5	Anti–Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Patients With Optic Neuritis. Archives of Neurology, 2012, 69, 752-6.	4.5	181
6	International multicenter examination of MOG antibody assays. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	180
7	Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases. Multiple Sclerosis Journal, 2016, 22, 1821-1829.	3.0	128
8	Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. Journal of Neurology, 2017, 264, 2420-2430.	3 . 6	120
9	Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. Journal of Neuroinflammation, 2017, 14, 208.	7.2	105
10	Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 897-905.	1.9	98
11	Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology, 2019, 93, e1867-e1872.	1.1	80
12	Fulminant demyelinating encephalomyelitis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e175.	6.0	75
13	MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. Journal of Neurology, 2018, 265, 845-855.	3.6	68
14	Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat. Acta Neuropathologica, 2019, 137, 467-485.	7.7	56
15	Highly encephalitogenic aquaporin 4-specific T cells and NMO-lgG jointly orchestrate lesion location and tissue damage in the CNS. Acta Neuropathologica, 2015, 130, 783-798.	7.7	55
16	NMDA receptor antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e141.	6.0	44
17	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. Journal of Neuroinflammation, 2020, 17, 262.	7.2	44
18	Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD. Acta Neuropathologica Communications, 2016, 4, 82.	5. 2	41

#	Article	IF	CITATIONS
19	Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1293-1296.	1.9	40
20	Comparison of Diagnostic Accuracy of Microscopy and Flow Cytometry in Evaluating N-Methyl-D-Aspartate Receptor Antibodies in Serum Using a Live Cell-Based Assay. PLoS ONE, 2015, 10, e0122037.	2.5	27
21	High association of MOG-lgG antibodies in children with bilateral optic neuritis. European Journal of Paediatric Neurology, 2020, 27, 86-93.	1.6	22
22	Nogo-B is associated with cytoskeletal structures in human monocyte-derived macrophages. BMC Research Notes, 2011, 4, 6.	1.4	20
23	Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome. Multiple Sclerosis Journal, 2022, 28, 1553-1561.	3.0	20
24	Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	16
25	NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders. Multiple Sclerosis and Related Disorders, 2021, 50, 102833.	2.0	15
26	Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord. PLoS ONE, 2016, 11, e0151244.	2.5	15
27	Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders. Journal of Neuroinflammation, 2016, 13, 176.	7.2	14
28	Antibodies to MOG in CSF only: pathological findings support the diagnostic value. Acta Neuropathologica, 2021, 141, 801-804.	7.7	14
29	Antibodies to aquaporin-1 are not present in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e160.	6.0	13
30	Epidemiology of Pediatric NMOSD in Germany and Austria. Frontiers in Neurology, 2020, 11, 415.	2.4	10
31	6-month SARS-CoV-2 antibody persistency in aÂTyrolian COVID-19 cohort. Wiener Klinische Wochenschrift, 2021, 133, 351-358.	1.9	10
32	Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells. Multiple Sclerosis Journal, 2015, 21, 651-655.	3.0	9
33	Decreased Frequency of Circulating Myelin Oligodendrocyte Glycoprotein B Lymphocytes in Patients with Relapsing-Remitting Multiple Sclerosis. Journal of Immunology Research, 2015, 2015, 1-12.	2.2	7
34	Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes. Acta Neuropathologica Communications, 2020, 8, 49.	5.2	5
35	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association. Frontiers in Immunology, 2021, 12, 769653.	4.8	3
36	Temporal Dynamics of MOG Antibodies in Children with Acquired Demyelinating Syndrome. Neuropediatrics, 2021, 52, .	0.6	2

3